Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Roche acquires key gene therapy player Spark Therapeutics for $4.8bn

Executive Summary

Roche acquired publicly traded gene therapy company Spark Therapeutics Inc. for $4.8bn, or $114.50 per share (a 128% premium), including $500mm of projected net cash at closing. Spark will continue to operate as an independent entity.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Contract
    • Payment Includes Cash
    • Full Acquisition

Related Companies

Advertisement
UsernamePublicRestriction

Register